Travere Therapeutics Inc Q4 2021 Earnings Call Transcript - Thomson StreetEvents

Travere Therapeutics Inc Q4 2021 Earnings Call Transcript

Travere Therapeutics Inc Q4 2021 Earnings Call Transcript - Thomson StreetEvents
Travere Therapeutics Inc Q4 2021 Earnings Call Transcript
Published Feb 24, 2022
Published Feb 24, 2022
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of TVTX.OQ earnings conference call or presentation 24-Feb-22 9:30pm GMT

  
Report Type:

Transcript

Source:
Company:
Travere Therapeutics Inc
Ticker
TVTX.OQ
Time
9:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : On FSGS, what would you consider to be supportive eGFR data in your opinion? And if that were not considered to be sufficient for filing, what would be required for a filing? Would you have to complete the entire study? Or could there be another interim analysis performed?


Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : Great. That's helpful. Thanks again and congrats on the progress. It's exciting to see you guys getting close to the finish line.


Question: Michelle Lim Gilson - Canaccord Genuity Corp., Research Division - Analyst : I guess a couple on pegtibatinase. You indicated when you presented the data in December that you were planning to meet with the FDA in the first quarter of this year to get aligned on a potential clinical outcome endpoint. I was just curious if you guys have had that meeting? And then when it comes to total homocysteine as a surrogate endpoint or as a biomarker, can you maybe discuss how established the link is with homocysteine and clinical outcomes in homocystinuria? And just maybe if the FDA does ask you to run a trial with a clinical outcome endpoint, what kind of options do you have? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. FEBRUARY 24, 2022 / 9:30PM, TVTX.OQ - Q4 2021 Travere Therapeutics Inc Earnings Call


Question: Michelle Lim Gilson - Canaccord Genuity Corp., Research Division - Analyst : Oh yes, they're very big fans.

Table Of Contents

Travere Therapeutics Inc to Discuss the Regulatory Update Call Transcript – 2022-10-13 – US$ 54.00 – Edited Transcript of TVTX.OQ conference call or presentation 13-Oct-22 8:30pm GMT

Travere Therapeutics Inc Q2 2022 Earnings Call Transcript – 2022-08-04 – US$ 54.00 – Edited Transcript of TVTX.OQ earnings conference call or presentation 4-Aug-22 12:00pm GMT

Travere Therapeutics Inc at Bank of America Healthcare Conference Transcript – 2022-05-10 – US$ 54.00 – Edited Transcript of TVTX.OQ presentation 10-May-22 11:00pm GMT

Travere Therapeutics Inc Q1 2022 Earnings Call Transcript – 2022-05-05 – US$ 54.00 – Edited Transcript of TVTX.OQ earnings conference call or presentation 5-May-22 8:30pm GMT

Travere Therapeutics Inc at Barclays Global Healthcare Conference Transcript – 2022-03-17 – US$ 54.00 – Edited Transcript of TVTX.OQ presentation 17-Mar-22 12:30pm GMT

Travere Therapeutics Inc to Discuss the Topline Results from the Ongoing Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria Call Transcript – 2021-12-15 – US$ 54.00 – Edited Transcript of TVTX.OQ conference call or presentation 15-Dec-21 1:30pm GMT

Travere Therapeutics Inc Q3 2021 Earnings Call Transcript – 2021-10-28 – US$ 54.00 – Edited Transcript of TVTX.OQ earnings conference call or presentation 28-Oct-21 8:30pm GMT

Travere Therapeutics Inc Topline Interim Results from the Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy Corporate Call Transcript – 2021-08-16 – US$ 54.00 – Edited Transcript of TVTX.OQ conference call or presentation 16-Aug-21 12:30pm GMT

Travere Therapeutics Inc Q2 2021 Earnings Call Transcript – 2021-07-29 – US$ 54.00 – Edited Transcript of TVTX.OQ earnings conference call or presentation 29-Jul-21 8:30pm GMT

Travere Therapeutics Inc to Discuss Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis Call Transcript – 2021-05-25 – US$ 54.00 – Edited Transcript of TVTX.OQ conference call or presentation 25-May-21 8:30pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Travere Therapeutics Inc Q4 2021 Earnings Call Transcript" Feb 24, 2022. Alacra Store. May 04, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q4-2021-Travere-Therapeutics-Inc-Earnings-Call-T15118615>
  
APA:
Thomson StreetEvents. (2022). Travere Therapeutics Inc Q4 2021 Earnings Call Transcript Feb 24, 2022. New York, NY: Alacra Store. Retrieved May 04, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q4-2021-Travere-Therapeutics-Inc-Earnings-Call-T15118615>
  
US$ 54.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.